DEO
Diageo plc
Beverages - Wineries & Distilleries
Market Cap$47.01B
5Y Perf.-39.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
DEO vs BEAM
Revenue, margins, valuation, and 5-year total return — side by side.
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.32B
5Y Perf.+26.5%
DEO vs BEAM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | DEO | BEAM |
|---|---|---|
| Industry | Beverages - Wineries & Distilleries | Biotechnology |
| Market Cap | $47.01B | $3.32B |
| Revenue (TTM) | $37.37B | $140M |
| Net Income (TTM) | $5.49B | $-80M |
| Gross Margin | 60.0% | -126.1% |
| Operating Margin | 27.9% | -274.6% |
| Forward P/E | 18.1x | — |
| Total Debt | $24.40B | $294M |
| Cash & Equiv. | $2.20B | $295M |
DEO vs BEAM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DEO
BEAM
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Diageo plc (DEO) | 100 | 60.2 | -39.8% |
| Beam Therapeutics I… (BEAM) | 100 | 126.5 | +26.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DEO vs BEAM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DEO leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Beam Therapeutics Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
DEO
Diageo plc
The Income Pick
DEO carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 12 yrs, beta 0.37, yield 4.9%
- Lower volatility, beta 0.37, current ratio 1.63x
- Beta 0.37, yield 4.9%, current ratio 1.63x
Best for: income & stability and sleep-well-at-night
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- 72.4% 10Y total return vs DEO's 11.5%
- 120.0% revenue growth vs DEO's -0.1%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BEAM | 120.0% revenue growth vs DEO's -0.1% |
| Quality / Margins | DEO | 14.7% margin vs BEAM's -57.2% |
| Stability / Safety | DEO | Beta 0.37 vs BEAM's 2.14 |
| Dividends | DEO | 4.9% yield; 12-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | BEAM | +102.2% vs DEO's -23.4% |
| Efficiency (ROA) | DEO | 14.7% ROA vs BEAM's -5.7%, ROIC 9.6% vs -31.1% |
DEO vs BEAM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
DEO vs BEAM — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDEOLAGGINGBEAM
BEAMBeam Therapeutics Inc.
2leads
DEODiageo plc
2leads
6 Total Categories
CATEGORYLEADERvs BEAMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DEO4/6
Valuation MetricsMultiples, price ratios, and targets
BEAM2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DEO6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
BEAM5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DEO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
DEO is the larger business by revenue, generating $37.4B annually — 267.4x BEAM's $140M. DEO is the more profitable business, keeping 14.7% of every revenue dollar as net income compared to BEAM's -57.2%. On growth, BEAM holds the edge at +2.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | DEODiageo plc | BEAMBeam Therapeutics… |
|---|---|---|
| RevenueTrailing 12 months | $37.4B | $140M |
| EBITDAEarnings before interest/tax | $11.6B | -$361M |
| Net IncomeAfter-tax profit | $5.5B | -$80M |
| Free Cash FlowCash after capex | $7.7B | -$360M |
| Gross MarginGross profit ÷ Revenue | +60.0% | -126.1% |
| Operating MarginEBIT ÷ Revenue | +27.9% | -2.7% |
| Net MarginNet income ÷ Revenue | +14.7% | -57.2% |
| FCF MarginFCF ÷ Revenue | +20.6% | -2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -29.1% | +2.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -24.1% | +3.1% |
DEO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
BEAM leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | DEODiageo plc | BEAMBeam Therapeutics… |
|---|---|---|
| Market CapShares × price | $47.0B | $3.3B |
| Enterprise ValueMkt cap + debt − cash | $69.2B | $3.3B |
| Trailing P/EPrice ÷ TTM EPS | 19.95x | -39.92x |
| Forward P/EPrice ÷ next-FY EPS est. | 18.07x | — |
| PEG RatioP/E ÷ EPS growth rate | 2.68x | — |
| EV / EBITDAEnterprise value multiple | 11.43x | — |
| Price / SalesMarket cap ÷ Revenue | 2.32x | 23.77x |
| Price / BookPrice ÷ Book value/share | 3.58x | 2.58x |
| Price / FCFMarket cap ÷ FCF | 17.51x | — |
BEAM leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
DEO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
DEO delivers a 54.0% return on equity — every $100 of shareholder capital generates $54 in annual profit, vs $-7 for BEAM. BEAM carries lower financial leverage with a 0.24x debt-to-equity ratio, signaling a more conservative balance sheet compared to DEO's 1.85x. On the Piotroski fundamental quality scale (0–9), DEO scores 5/9 vs BEAM's 4/9, reflecting solid financial health.
| Metric | DEODiageo plc | BEAMBeam Therapeutics… |
|---|---|---|
| ROE (TTM)Return on equity | +54.0% | -7.3% |
| ROA (TTM)Return on assets | +14.7% | -5.7% |
| ROICReturn on invested capital | +9.6% | -31.1% |
| ROCEReturn on capital employed | +11.7% | -33.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 1.85x | 0.24x |
| Net DebtTotal debt minus cash | $22.2B | -$1M |
| Cash & Equiv.Liquid assets | $2.2B | $295M |
| Total DebtShort + long-term debt | $24.4B | $294M |
| Interest CoverageEBIT ÷ Interest expense | 5.71x | -9.14x |
DEO leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
BEAM leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DEO five years ago would be worth $5,723 today (with dividends reinvested), compared to $4,612 for BEAM. Over the past 12 months, BEAM leads with a +102.2% total return vs DEO's -23.4%. The 3-year compound annual growth rate (CAGR) favors BEAM at -1.0% vs DEO's -19.9% — a key indicator of consistent wealth creation.
| Metric | DEODiageo plc | BEAMBeam Therapeutics… |
|---|---|---|
| YTD ReturnYear-to-date | -2.0% | +19.1% |
| 1-Year ReturnPast 12 months | -23.4% | +102.2% |
| 3-Year ReturnCumulative with dividends | -48.7% | -3.0% |
| 5-Year ReturnCumulative with dividends | -42.8% | -53.9% |
| 10-Year ReturnCumulative with dividends | +11.5% | +72.4% |
| CAGR (3Y)Annualised 3-year return | -19.9% | -1.0% |
BEAM leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — DEO and BEAM each lead in 1 of 2 comparable metrics.
Risk & Volatility
DEO is the less volatile stock with a 0.37 beta — it tends to amplify market swings less than BEAM's 2.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BEAM currently trades 88.7% from its 52-week high vs DEO's 72.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DEODiageo plc | BEAMBeam Therapeutics… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.37x | 2.14x |
| 52-Week HighHighest price in past year | $116.69 | $36.44 |
| 52-Week LowLowest price in past year | $72.46 | $15.35 |
| % of 52W HighCurrent price vs 52-week peak | +72.5% | +88.7% |
| RSI (14)Momentum oscillator 0–100 | 53.3 | 50.7 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 2.1M |
Evenly matched — DEO and BEAM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates DEO as "Hold" and BEAM as "Buy". Consensus price targets imply 46.6% upside for DEO (target: $124) vs 26.3% for BEAM (target: $41). DEO is the only dividend payer here at 4.88% yield — a key consideration for income-focused portfolios.
| Metric | DEODiageo plc | BEAMBeam Therapeutics… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $124.00 | $40.83 |
| # AnalystsCovering analysts | 35 | 27 |
| Dividend YieldAnnual dividend ÷ price | +4.9% | — |
| Dividend StreakConsecutive years of raises | 12 | — |
| Dividend / ShareAnnual DPS | $4.13 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DEO leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BEAM leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Best OverallDiageo plc (DEO)Leads 2 of 6 categories
Loading custom metrics...
DEO vs BEAM: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is DEO or BEAM a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -0. 1% for Diageo plc (DEO). Diageo plc (DEO) offers the better valuation at 19. 9x trailing P/E (18. 1x forward), making it the more compelling value choice. Analysts rate Beam Therapeutics Inc. (BEAM) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DEO or BEAM?
Over the past 5 years, Diageo plc (DEO) delivered a total return of -42.
8%, compared to -53. 9% for Beam Therapeutics Inc. (BEAM). Over 10 years, the gap is even starker: BEAM returned +72. 4% versus DEO's +11. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DEO or BEAM?
By beta (market sensitivity over 5 years), Diageo plc (DEO) is the lower-risk stock at 0.
37β versus Beam Therapeutics Inc. 's 2. 14β — meaning BEAM is approximately 484% more volatile than DEO relative to the S&P 500. On balance sheet safety, Beam Therapeutics Inc. (BEAM) carries a lower debt/equity ratio of 24% versus 185% for Diageo plc — giving it more financial flexibility in a downturn.
04Which is growing faster — DEO or BEAM?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus -0. 1% for Diageo plc (DEO). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to -38. 7% for Diageo plc. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DEO or BEAM?
Diageo plc (DEO) is the more profitable company, earning 11.
6% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DEO leads at 21. 4% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is DEO or BEAM more undervalued right now?
Analyst consensus price targets imply the most upside for DEO: 46.
6% to $124. 00.
07Which pays a better dividend — DEO or BEAM?
In this comparison, DEO (4.
9% yield) pays a dividend. BEAM does not pay a meaningful dividend and should not be held primarily for income.
08Is DEO or BEAM better for a retirement portfolio?
For long-horizon retirement investors, Diageo plc (DEO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
37), 4. 9% yield). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DEO: +11. 5%, BEAM: +72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between DEO and BEAM?
These companies operate in different sectors (DEO (Consumer Defensive) and BEAM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: DEO is a mid-cap income-oriented stock; BEAM is a small-cap high-growth stock. DEO pays a dividend while BEAM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(DEO: -29.1% · BEAM: 279.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.